IGC · Igc Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $328.0K | - | $191.0K | $272.0K | $257.0K | $412.0K | $555.0K | $204.0K | $291.0K | $212.0K |
| Cost of Revenue | $174.0K | - | $92.0K | $109.0K | $153.0K | $214.0K | $300.0K | $71.0K | $117.0K | $70.0K |
| Gross Profit | $154.0K | - | $99.0K | $163.0K | $104.0K | $198.0K | $255.0K | $133.0K | $174.0K | $142.0K |
| R&D | $851.0K | - | $1.59M | $889.0K | $852.0K | $917.0K | $747.0K | $903.0K | $1.27M | $1.39M |
| SG&A | $1.21M | - | $1.41M | $1.67M | $1.13M | $1.04M | $1.65M | $2.23M | $1.40M | $1.55M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $141.0K | - | $105.0K | $162.0K | $144.0K | $145.0K | $155.0K | $140.0K | $140.0K | $162.0K |
| Operating Income | ($1.91M) | - | ($2.90M) | ($2.40M) | ($1.88M) | ($1.76M) | ($2.14M) | ($3.00M) | ($2.49M) | ($2.80M) |
| Interest Expense | $1.0K | - | - | $1.0K | - | - | $1.0K | - | - | $1.0K |
| Income Tax | $0 | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($1.60M) | - | ($1.82M) | ($2.38M) | ($1.83M) | ($1.72M) | ($2.08M) | ($5.59M) | ($2.45M) | ($2.79M) |
| EPS - Basic | ($0.02) | - | ($0.02) | - | ($0.02) | ($0.05) | - | - | - | - |
| EPS - Diluted | ($0.02) | - | ($0.02) | - | ($0.09) | ($0.05) | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $207.0K | $900.0K | $1.10M | $405.0K | $470.0K | $1.55M | $1.20M | $1.38M | $3.03M | $3.20M |
| Accounts Receivable | $37.0K | $12.0K | $41.0K | $34.0K | $49.0K | $44.0K | $39.0K | $92.0K | $137.0K | $107.0K |
| Inventory | $638.0K | $640.0K | $658.0K | $1.36M | $1.43M | $1.51M | $1.54M | $1.93M | $2.64M | $2.65M |
| Accounts Payable | $1.25M | $1.01M | $628.0K | $883.0K | $835.0K | $768.0K | $773.0K | $648.0K | $549.0K | $530.0K |
| Current Assets | $1.15M | $1.79M | $2.00M | $2.90M | $3.05M | $4.25M | $3.71M | $3.58M | $6.12M | $6.47M |
| Total Assets | $9.19M | $9.71M | $9.74M | $8.75M | $9.08M | $10.37M | $9.90M | $11.26M | $16.51M | $17.18M |
| Current Liabilities | $2.87M | $2.16M | $1.51M | $2.26M | $2.66M | $2.80M | $2.34M | $1.94M | $2.11M | $1.90M |
| Long-term Debt | $133.0K | $131.0K | $132.0K | $134.0K | $134.0K | $135.0K | $137.0K | $138.0K | $139.0K | $141.0K |
| Total Liabilities | $3.06M | $2.29M | $1.65M | $2.42M | $2.82M | $2.99M | $2.58M | $2.21M | $2.41M | $2.27M |
| Stockholders' Equity | $6.12M | $7.42M | $8.09M | $6.33M | $6.26M | $7.38M | $7.32M | $9.05M | $14.10M | $14.91M |
| Retained Earnings | ($127.29M) | ($124.89M) | ($122.83M) | ($120.74M) | ($119.59M) | ($117.76M) | ($113.67M) | ($110.78M) | ($105.19M) | ($100.67M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.41M) | - | - | ($1.75M) | - | - | ($1.47M) | - | - | ($2.20M) |
| Investing Cash Flow | $580.0K | - | - | ($131.0K) | - | - | ($5.0K) | - | - | ($158.0K) |
| Financing Cash Flow | $851.0K | - | - | $2.51M | - | - | ($1.0K) | - | - | ($1.0K) |
| CapEx | $8.0K | - | - | $38.0K | - | - | $20.0K | - | - | $127.0K |
| Free Cash Flow | ($1.42M) | - | - | ($1.79M) | - | - | ($1.49M) | - | - | ($2.32M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 47.0% | - | 51.8% | 59.9% | 40.5% | 48.1% | 45.9% | 65.2% | 59.8% | 67.0% |
| Operating margin | -580.8% | - | -1517.8% | -880.9% | -730.7% | -427.2% | -385.4% | -1469.6% | -856.0% | -1321.7% |
| EBITDA margin | -537.8% | - | -1462.8% | -821.3% | -674.7% | -392.0% | -357.5% | -1401.0% | -807.9% | -1245.3% |
| Net margin | -487.5% | - | -953.4% | -874.3% | -711.7% | -416.7% | -373.9% | -2739.7% | -842.3% | -1313.7% |
| Free cash flow margin | -431.4% | - | - | -658.1% | - | - | -268.1% | - | - | -1095.8% |
| FCF / Net income | 0.88 | - | - | 0.75 | - | - | 0.72 | - | - | 0.83 |
| R&D / Revenue | 259.5% | - | 831.4% | 326.8% | 331.5% | 222.6% | 134.6% | 442.6% | 435.7% | 657.5% |
| SG&A / Revenue | 368.3% | - | 738.2% | 614.0% | 439.7% | 252.7% | 296.8% | 1092.2% | 480.1% | 731.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.4% | - | -18.7% | -27.2% | -20.1% | -16.6% | -21.0% | -49.6% | -14.8% | -16.2% |
| Return on equity | -26.1% | - | -22.5% | -37.6% | -29.2% | -23.3% | -28.3% | -61.7% | -17.4% | -18.7% |
| Return on invested capital | -24.1% | - | -27.8% | -29.3% | -23.2% | -18.5% | -22.7% | -25.8% | -13.8% | -14.7% |
| Liquidity | ||||||||||
| Current ratio | 0.40 | 0.83 | 1.32 | 1.28 | 1.15 | 1.52 | 1.58 | 1.85 | 2.90 | 3.41 |
| Quick ratio | 0.18 | 0.53 | 0.89 | 0.68 | 0.61 | 0.98 | 0.93 | 0.86 | 1.65 | 2.01 |
| Cash ratio | 0.07 | 0.42 | 0.73 | 0.18 | 0.18 | 0.55 | 0.51 | 0.71 | 1.44 | 1.68 |
| Leverage | ||||||||||
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Debt / Assets | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1905.0x | - | - | -2396.0x | - | - | -2139.0x | - | - | -2802.0x |
| Equity multiplier | 1.50 | 1.31 | 1.20 | 1.38 | 1.45 | 1.41 | 1.35 | 1.24 | 1.17 | 1.15 |
| Liabilities / Assets | 0.33 | 0.24 | 0.17 | 0.28 | 0.31 | 0.29 | 0.26 | 0.20 | 0.15 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.02 | 0.03 | 0.03 | 0.04 | 0.06 | 0.02 | 0.02 | 0.01 |
| Inventory turnover | 0.27 | - | 0.14 | 0.08 | 0.11 | 0.14 | 0.19 | 0.04 | 0.04 | 0.03 |
| Days sales outstanding | 41d | - | 78d | 46d | 70d | 39d | 26d | 165d | 172d | 184d |
| Days inventory outstanding | 1338d | - | 2611d | 4554d | 3419d | 2575d | 1874d | 9896d | 8223d | 13823d |
| Days payable outstanding | 2633d | - | 2492d | 2957d | 1992d | 1310d | 940d | 3331d | 1713d | 2764d |
| Cash conversion cycle | -1253d | - | 197d | 1643d | 1496d | 1305d | 959d | 6729d | 6683d | 11244d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.1x | - | 4.7x | - | 4.2x | 4.4x | - | - | - | - |
| P / S | 57.7x | - | 198.9x | - | 102.7x | 79.3x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 20.6% | - | -53.6% | -51.0% | 26.0% | 41.6% | 161.8% | -38.6% | 44.1% | 175.3% |
| Revenue CAGR (3y) | 15.7% | - | -1.8% | 52.3% | 21.9% | 94.5% | -1.7% | 23.6% | 32.5% | -49.5% |
| Revenue CAGR (5y) | -10.9% | - | 8.8% | -30.3% | -14.8% | -25.7% | -17.8% | -30.8% | -18.5% | 32.0% |
| Gross profit growth (YoY) | -5.5% | - | -50.0% | -36.1% | -21.8% | 13.8% | 79.6% | 30.4% | 28.9% | 446.2% |
| Operating income growth (YoY) | 20.5% | - | -64.7% | -12.0% | 37.4% | 29.3% | 23.7% | -31.6% | -0.1% | -27.7% |
| Net income growth (YoY) | 32.8% | - | -6.1% | -14.6% | 67.3% | 29.9% | 25.5% | -148.5% | -0.4% | -55.8% |
| EPS growth (YoY) | - | - | 60.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 20.9% | - | - | -20.3% | - | - | 35.9% | - | - | -19.5% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3.3% | - | 9.7% | -13.5% | -30.9% | -47.7% | -50.9% | -50.6% | -30.0% | -37.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-03-31.
Product / service
$2.71M totalPlant And Cannabinoid$1.27M · 47.0%
Tolling White Labeling Service$1.16M · 42.8%
Infrastructure Segment$164.0K · 6.1%
Wellness And Lifestyle$113.0K · 4.2%
Geographic
$1.27M totalUS$1.27M · 99.8%
CO$2.0K · 0.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IGC Pharma against the 5 most active filers in the same SIC group.